Cerdulatinib is primarily used in the research and development of treatments for hematologic malignancies, particularly B-cell lymphomas and leukemias. It functions as a dual inhibitor of JAK (Janus kinase) and SYK (spleen tyrosine kinase), two signaling proteins involved in immune cell activation and cancer cell proliferation. By blocking these pathways, cerdulatinib helps suppress abnormal immune signaling and tumor growth in certain blood cancers. It has shown promise in preclinical and clinical studies for patients with relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). Its dual inhibition mechanism offers a targeted approach that may overcome resistance seen with single-pathway inhibitors. Cerdulatinib is also being investigated for use in autoimmune and inflammatory conditions due to its modulation of immune signaling pathways, though its primary focus remains in oncology research.